The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
Open accessAbstract
Clustered, regularly interspaced, short palindromic repeat (CRISPR) RNA-guided nucleases (RGNs) have rapidly emerged as a facile and efficient platform for genome editing. Here, we use a human cell-based reporter assay to characterize off-target cleavage of CRISPR-associated (Cas)9-based RGNs. We find that single and double mismatches are tolerated to varying degrees depending on their position along the guide RNA (gRNA)-DNA interface. We also readily detected off-target alterations induced by four out of six RGNs targeted to endogenous loci in human cells by examination of partially mismatched sites. The off-target sites we identified harbored up to five mismatches and many were mutagenized with frequencies comparable to (or higher than) those observed at the intended on-target site. Our work demonstrates that RGNs can be highly active even with imperfectly matched RNA-DNA interfaces in human cells, a finding that might confound their use in research and therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in-depth studies on the outcomes of Cas9-induced double-strand break (DSB) repair have shown significant off-target effects, which resulted in substitution, insertion, deletion, and DNA translocation.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Defective off-target binding and cleaving can result in collateral mutagenesis induced by the error-prone repair of DSB by NHEJ [106,107].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [107]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For example, a study demonstrated that manipulating Cas9's biophysical attributes, such as minimizing nonspecific RNA-DNA interactions, significantly reduces off-target mutations while maintaining high on-target efficiency.”
From Hybrid Neural Networks for Off-Target Prediction in Gene Editing: Integrating Sequence and Biophysical Features (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“A study reported highfrequency off-target mutagenesis in transduced human cell lines after SpCas9 delivery [108].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [108]
In the citing paper
“Using a VEGFA sgRNA with well-characterized off-target sites24, we observed that transient Cas9 expression by mRNA delivery can substantially reduce off-target genome editing in cells (Fig. 1f–h).”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [24]
In the citing paper
“as mentioned in several recent publications, Cas9 tolerates mismatches between the guide RNA and target DNA in a sequence-dependent manner and potentially tolerates up to five target mismatches in human cells [12], [24], [25], [26], [27], thereby promoting undesired off-target mutations.”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [24]
In the citing paper
“non-specific cleavage may occur in the cellular genome [12], [24], [25], [26], [27].”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [24]
In the citing paper
“Because the sequence specificity of Streptococcus pyogenes Cas9 tolerates 4 mismatches between the gRNA and complementary sequence”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [24]
In the citing paper
“Collectively, these studies indicate that although each base within the 20 nt guide sequence contributes to overall specificity”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
In the citing paper
“However, it has been recently shown that CRISPR/Cas9 system can be highly active even when mismatches occur between gRNA and their DNA targets”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
In the citing paper
“multiple mismatches between the guide RNA and its complementary target DNA sequence can be tolerated depending on the quantity, position, and base identity of mismatches [87,90,91,93], all of which contribute to potential off-target activity.”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
In the citing paper
“and off-target mutations occur at endogenous loci in human cells with high frequency [90,91,92].”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
RNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
RNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,023
Shahi, N., Mallik, S. K., & Sarma, D. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737423 · Cited by 59
CRISPR/Cas9 system: a reliable and facile genome editing tool in modern biology
Javaid, D., Ganie, S. Y., Hajam, Y. A., & Reshi, M. S. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07880-6 · Cited by 65
Bacteriophage strategies for overcoming host antiviral immunity
Gao, Z., & Feng, Y. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1211793 · Cited by 67
Current trends of clinical trials involving CRISPR/Cas systems
Zhang, S., Wang, Y., Mao, D., Wang, Y., Zhang, H., Pan, Y., Wang, Y., Teng, S., & Huang, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1292452 · Cited by 62
Microbial Genome Editing with CRISPR–Cas9: Recent Advances and Emerging Applications Across Sectors
Dudeja, C., Mishra, A., Ali, A., Singh, P. P., & Jaiswal, A. K. (2025) · Fermentation · doi:10.3390/fermentation11070410 · Cited by 70
Kratochwil, C. F., & Meyer, A. (2014) · BioEssays · doi:10.1002/bies.201400142 · Cited by 59
Precision genome editing: A small revolution for glycobiology
Steentoft, C., Bennett, E., Schjoldager, K. T.-B. G., Vakhrushev, S. Y., Wandall, H. H., & Clausen, H. (2014) · Glycobiology · doi:10.1093/glycob/cwu046 · Cited by 62
Kujoth, G. C., Sullivan, T. D., Merkhofer, R. M., Lee, T.-J., Wang, H., Brandhorst, T. T., Wüthrich, M., & Klein, B. S. (2018) · mBio · doi:10.1128/mbio.00412-18 · Cited by 58
Bioelectric-calcineurin signaling module regulates allometric growth and size of the zebrafish fin
Daane, J. M., Lanni, J. S., Rothenberg, I., Seebohm, G., Higdon, C. W., Johnson, S. L., & Harris, M. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-28450-6 · Cited by 58
CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson’s Disease
Safari, F., Hatam, G., Behzad‐Behbahani, A., Tabar, V. R., Barekati‐Mowahed, M., Petramfar, P., & Khademi, F. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00761-w · Cited by 66
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 59
Ma, L., Ruan, J., Song, J. W., Wen, L., Yang, D., Zhao, J., Xia, X., Chen, Y. E., Zhang, J., & Xu, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19842-2 · Cited by 60
Hu, J. H., Davis, K. M., & Liu, D. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.009 · Cited by 61
Chaikind, B., Bessen, J. L., Thompson, D. B., Hu, J. H., & Liu, D. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw707 · Cited by 57
CRISPR/Cas9, a powerful tool to target human herpesviruses
van Diemen, F. R., & Lebbink, R. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12694 · Cited by 59
The CRB1 Complex: Following the Trail of Crumbs to a Feasible Gene Therapy Strategy
Quinn, P. M. J., Pellissier, L. P., & Wijnholds, J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00175 · Cited by 59
Motta, B. M., Pramstaller, P. P., Hicks, A. A., & Rossini, A. (2017) · Stem Cells International · doi:10.1155/2017/8960236 · Cited by 64
Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout
Knopp, Y., Geis, F. K., Heckl, D., Horn, S., Neumann, T., Kuehle, J., Meyer, J., Fehse, B., Baum, C., Morgan, M. A., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.006 · Cited by 63
Expanding the CRISPR Toolbox with ErCas12a in Zebrafish and Human Cells
Wierson, W. A., Simone, B. W., WareJoncas, Z., Mann, C. M., Welker, J. M., Kar, B., Emch, M. J., Friedberg, I., Gendron, W. A. C., Barry, M. A., et al. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0026 · Cited by 57
Progress and challenges towards CRISPR/Cas clinical translation
Rosenblum, D., Gutkin, A., Dammes, N., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.004 · Cited by 61
Establishing the allosteric mechanism in CRISPR‐Cas9
Nierzwicki, Ł., Arantes, P. R., Saha, A., & Palermo, G. (2020) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1503 · Cited by 58
Srikanth, P., & Young‐Pearse, T. L. (2014) · Journal of Neurogenetics · doi:10.3109/01677063.2014.881358 · Cited by 61
CRISPR-based gene expression control for synthetic gene circuits
Santos‐Moreno, J., & Schaerli, Y. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200020 · Cited by 59
Schmidt, M. J., Gupta, A. K., Bednarski, C., Gehrig-Giannini, S., Richter, F. M., Pitzler, C., Gamalinda, M., Galonska, C., Takeuchi, R., Wang, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24454-5 · Cited by 58
The Role of Recombinant AAV in Precise Genome Editing
Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.799722 · Cited by 63
Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing
Fang, T., Cao, X., Ibnat, M., & Chen, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01570-y · Cited by 63
Identification of a novel cis-regulatory element essential for immune tolerance
LaFlam, T. N., Seumois, G., Miller, C. N., Lwin, W. W., Fasano, K. J., Waterfield, M. R., Proekt, I., Vijayanand, P., & Anderson, M. S. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151069 · Cited by 57
The application of genome editing in studying hearing loss
Zou, B., Mittal, R., Grati, M., Lu, Z., Shu, Y., Tao, Y., Feng, Y., Xie, D., Kong, W., Yang, S., et al. (2015) · Hearing Research · doi:10.1016/j.heares.2015.04.016 · Cited by 57
Gene editing in mouse zygotes using the CRISPR/Cas9 system
Wefers, B., Bashir, S., Rossius, J., Wurst, W., & Kühn, R. (2017) · Methods · doi:10.1016/j.ymeth.2017.02.008 · Cited by 60
CRISPR/Cas9 cleavage efficiency regression through boosting algorithms and Markov sequence profiling
Peng, H., Zheng, Y., Blumenstein, M., Tao, D., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty298 · Cited by 57
Klompe, S. E., & Sternberg, S. H. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0012 · Cited by 57
CRISPR-Based Tools in Immunity
Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 57
Engineering designer beta cells with a CRISPR-Cas9 conjugation platform
Lim, D., Sreekanth, V., Cox, K. J., Law, B. K., Wagner, B. K., Karp, J. M., & Choudhary, A. (2020) · Nature Communications · doi:10.1038/s41467-020-17725-0 · Cited by 59
Bannister, S., Antonova, O., Polo, A., Lohs, C., Hallay, N., Valinciute, A., Raible, F., & Tessmar-Raible, K. (2014) · Genetics · doi:10.1534/genetics.113.161091 · Cited by 56
“The initial version of the system caused high numbers of offtarget mutations (Fu et al. 2013), which was improved by the simultaneous use of two sgRNAs and a mutant nickase version of the Cas9 protein (Ran et al. 2013) and most recently by shortening the length of the sgRNA (Fu et al. 2014).”
BackgroundEngineering the Caenorhabditis elegans genome with CRISPR/Cas9
Waaijers, S., & Boxem, M. (2014) · Methods · doi:10.1016/j.ymeth.2014.03.024 · Cited by 54
Improving Precise CRISPR Genome Editing by Small Molecules: Is there a Magic Potion?
Bischoff, N., Wimberger, S., Maresca, M., & Brakebusch, C. (2020) · Cells · doi:10.3390/cells9051318 · Cited by 58
Zhang, G., Zeng, T., Dai, Z., & Dai, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.03.001 · Cited by 64
Inturi, R., & Jemth, P. (2021) · Virology · doi:10.1016/j.virol.2021.07.005 · Cited by 55
Protein Inhibitors of CRISPR-Cas9
Bondy‐Denomy, J. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00831 · Cited by 56
Fei, J., Lou, W. P.-K., Knapp, D., Murawala, P., Gerber, T., Taniguchi, Y., Nowoshilow, S., Khattak, S., & Tanaka, E. M. (2018) · Nature Protocols · doi:10.1038/s41596-018-0071-0 · Cited by 57
SNP-CRISPR: A Web Tool for SNP-Specific Genome Editing
Chen, C., Rodiger, J., Chung, V., Viswanatha, R., Mohr, S. E., Hu, Y., & Perrimon, N. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400904 · Cited by 57
CRISPR-Cas Activators for Engineering Gene Expression in Higher Eukaryotes
Casas-Mollano, J. A., Zinselmeier, M. H., Erickson, S. E., & Smanski, M. J. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0064 · Cited by 58
Cytosine base editing systems with minimized off-target effect and molecular size
Li, A., Mitsunobu, H., Yoshioka, S., Suzuki, T., Kondo, A., & Nishida, K. (2022) · Nature Communications · doi:10.1038/s41467-022-32157-8 · Cited by 57
Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease
Uchida, N., Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., DiNicola, J., Shibata, Y., Hinds, M., Gudmundsdottir, B., Haro-Mora, J. J., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.022 · Cited by 55
Methods and applications of CRISPR/Cas system for genome editing in stem cells
Yang, G., & Huang, X. (2019) · Cell Regeneration · doi:10.1016/j.cr.2019.08.001 · Cited by 55
Confalonieri, M., Carelli, M., Gianoglio, S., Moglia, A., Biazzi, E., & Tava, A. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.690231 · Cited by 55
Systematic decomposition of sequence determinants governing CRISPR/Cas9 specificity
Fu, R., He, W., Dou, J., Villarreal, O. D., Bedford, E., Wang, H. H., Hou, C., Zhang, L., Wang, Y., Ma, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28028-x · Cited by 59
Masarwy, R., Stotsky‐Oterin, L., Elisha, A., Hazan‐Halevy, I., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115359 · Cited by 59
Biscaia-Caleiras, M., Fonseca, N. A., Lourenço, A. S., Moreira, J. N., & Simões, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.021 · Cited by 57
Synthesis of an arrayed sgRNA library targeting the human genome
Schmidt, T., Schmid-Burgk, J. L., & Hornung, V. (2015) · Scientific Reports · doi:10.1038/srep14987 · Cited by 54
Engineering T Cells to Functionally Cure HIV-1 Infection
Leibman, R. S., & Riley, J. L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.70 · Cited by 59
Flores, C., Mojadidi, M., Phillips, J., Kuo, C. Y., Lai, S. Y., Lill, G. R., Cooper, A. R., Kaufman, M. L., Urbinati, F., Wang, X., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.52 · Cited by 53
Yiu, G. C., Tieu, E., Nguyen, A. T., Wong, B. M., & Smit‐McBride, Z. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20296 · Cited by 55
Epigenetic Editing of Ascl1 Gene in Neural Stem Cells by Optogenetics
Lo, C., Choudhury, S. R., Irudayaraj, J., & Zhou, F. (2017) · Scientific Reports · doi:10.1038/srep42047 · Cited by 55
Yang, H., & Chen, P. (2017) · Virus Research · doi:10.1016/j.virusres.2017.06.010 · Cited by 54
Computational Tools and Resources Supporting CRISPR-Cas Experiments
Śledziński, P., Nowaczyk, M., & Olejniczak, M. (2020) · Cells · doi:10.3390/cells9051288 · Cited by 57
Generation of B Cell-Deficient Pigs by Highly Efficient CRISPR/Cas9-Mediated Gene Targeting
Chen, F., Wang, Y., Yuan, Y., Zhang, W., Ren, Z., Jin, Y., Liu, X., Xiong, Q., Chen, Q., Zhang, M., et al. (2015) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.05.002 · Cited by 54
CRISPR-Cas systems: ushering in the new genome editing era
Rojo, F. P., Nyman, R. K. M., Johnson, A. A. T., Pazos-Navarro, M., Ryan, M. H., Erskine, W., & Kaur, P. (2018) · Bioengineered · doi:10.1080/21655979.2018.1470720 · Cited by 58
Engineering subtle targeted mutations into the mouse genome
Menke, D. B. (2013) · genesis · doi:10.1002/dvg.22422 · Cited by 53
Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing
Rabinowitz, R., & Offen, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.009 · Cited by 58
Sequence-independent RNA sensing and DNA targeting by a split domain CRISPR–Cas12a gRNA switch
Collins, S. P., Rostain, W., Liao, C., & Beisel, C. L. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab100 · Cited by 52
CRISPRon/off: CRISPR/Cas9 on- and off-target gRNA design
Anthon, C., Corsi, G. I., & Gorodkin, J. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac697 · Cited by 54
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 61
From dead leaf, to new life: TAL effectors as tools for synthetic biology
de Lange, O., Binder, A., & Lahaye, T. (2014) · The Plant Journal · doi:10.1111/tpj.12431 · Cited by 56
Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells
Kim, H. S., Bernitz, J. M., Lee, D., & Lemischka, I. R. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0167 · Cited by 57
Parikh, B. A., Beckman, D. L., Patel, S. J., White, J. M., & Yokoyama, W. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116484 · Cited by 55
Nakagawa, Y., Sakuma, T., Sakamoto, T., Ohmuraya, M., Nakagata, N., & Yamamoto, T. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0144-x · Cited by 55
CRISPR-based self-cleaving mechanism for controllable gene delivery in human cells
Moore, R. L., Spinhirne, A., Lai, M. J., Preisser, S., Li, Y., Kang, T., & Bleris, L. G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1326 · Cited by 54
Using RNA as Molecular Code for Programming Cellular Function
Kushwaha, M., Rostain, W., Prakash, S., Duncan, J. N., & Jaramillo, A. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00297 · Cited by 56
Genome editing in nonhuman primates: approach to generating human disease models
Chen, Y., Niu, Y., & Ji, W. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12469 · Cited by 54
Heritability of targeted gene modifications induced by plant-optimized CRISPR systems
Mao, Y., Botella, J. R., & Zhu, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2380-1 · Cited by 55
Mao, C., Livezey, M. R., Kim, J. E., & Shapiro, D. J. (2016) · Scientific Reports · doi:10.1038/srep34753 · Cited by 57
Precision gene editing technology and applications in nephrology
WareJoncas, Z., Campbell, J. M., Martínez‐Gálvez, G., Gendron, W. A. C., Barry, M. A., Harris, P. C., Sussman, C. R., & Ekker, S. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0047-x · Cited by 61
High-level correction of the sickle mutation is amplified in vivo during erythroid differentiation
Magis, W., DeWitt, M. A., Wyman, S. K., Vu, J. T., Heo, S., Shao, S. J., Hennig, F., Romero, Z. G., Campo-Fernández, B., Said, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104374 · Cited by 53
Cas9-Based Genome Editing in Zebrafish
Gonzales, A. P. W., & Yeh, J.-R. J. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801185-0.00018-0 · Cited by 56
Catalytic-state structure and engineering of Streptococcus thermophilus Cas9
Zhang, Y., Zhang, H., Xu, X., Wang, Y., Chen, W., Wang, Y., Wu, Z., Tang, N., Wang, Y., Zhao, S., et al. (2020) · Nature Catalysis · doi:10.1038/s41929-020-00506-9 · Cited by 49
Zhou, W., Cui, H., Ying, L., & Yu, X. (2018) · Angewandte Chemie · doi:10.1002/ange.201806941 · Cited by 54
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 63
DNA base editing in nuclear and organellar genomes
Tan, J., Forner, J., Karcher, D., & Bock, R. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.06.015 · Cited by 57
Arbab, M., Srinivasan, S., Hashimoto, T., Geijsen, N., & Sherwood, R. I. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.09.022 · Cited by 49
Improved Genome Editing in Human Cell Lines Using the CRISPR Method
Munoz, I. M., Szyniarowski, P., Toth, R. L., Rouse, J. W., & Lachaud, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109752 · Cited by 53
Control and Eradication Strategies of Hepatitis B Virus
Shih, C., Chou, S.-F., Yang, C.-C., Huang, J., Choijilsuren, G., & Jhou, R. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.05.006 · Cited by 53
Survival and Evolution of CRISPR–Cas System in Prokaryotes and Its Applications
Shabbir, M. A. B., Hao, H., Shabbir, M. Z., Hussain, H. I., Zahid, I., Ahmed, S., Sattar, A., Iqbal, M., Li, J., & Yuan, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00375 · Cited by 59
Lu, J., Shao, Y., Qin, X., Liu, D., Chen, A., Li, D., Liu, M., & Wang, X. (2017) · Scientific Reports · doi:10.1038/srep42922 · Cited by 53
Bollen, Y., Post, J. B., Koo, B., & Snippert, H. J. G. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky571 · Cited by 53
Peng, H., Zheng, Y., Zhao, Z., Liu, T., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty558 · Cited by 57
Elaswad, A., Khalil, K. M., Ye, Z., Liu, Z., Liu, S., Peatman, E., Odin, R., Vo, K. M., Drescher, D., Gosh, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34738-4 · Cited by 51
Targeted exon skipping with AAV-mediated split adenine base editors
Winter, J., Luu, A., Gapinske, M., Manandhar, S., Shirguppe, S., Woods, W. S., Song, J. S., & Pérez‐Piñera, P. (2019) · Cell Discovery · doi:10.1038/s41421-019-0109-7 · Cited by 56
Taghbalout, A., Du, M., Jillette, N., Rosikiewicz, W., Rath, A., Heinen, C. D., Li, S., & Cheng, A. W. (2019) · Nature Communications · doi:10.1038/s41467-019-12339-7 · Cited by 53
CRISPR technology: The engine that drives cancer therapy
Zhang, M., Eshraghian, E. A., Jammal, O. A., Zhang, Z.-B., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111007 · Cited by 54
Optogenetic Medicine: Synthetic Therapeutic Solutions Precision-Guided by LightPreprint
Ye, H., & Fussenegger, M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034371 · Cited by 55
Ren, D., Fisson, S., Dalkara, D., & Ail, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091973 · Cited by 52
CRISPR interference and its applications
Ghavami, S., & Pandi, A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.007 · Cited by 55
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 60
Self-citationHow data science and AI-based technologies impact genomics
Jing, L., & Ngiam, K. Y. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-438 · Cited by 53
Review: Recent Applications of Gene Editing in Fish Species and Aquatic Medicine
Gutási, A., Hammer, S. E., El‐Matbouli, M., & Saleh, M. (2023) · Animals · doi:10.3390/ani13071250 · Cited by 54
In the business of base editors: Evolution from bench to bedside
Porto, E. M., & Komor, A. C. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002071 · Cited by 53
Baysal, C., Bortesi, L., Zhu, C., Farré, G., Schillberg, S., & Christou, P. (2016) · Molecular Breeding · doi:10.1007/s11032-016-0533-4 · Cited by 52
Ligtenberg, M. A., de Coaña, Y. P., Shmushkovich, T., Yoshimoto, Y., Truxová, I., Yang, Y., Betancur-Boissel, M., Eliseev, A. V., Wolfson, A. D., & Kiessling, R. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.015 · Cited by 53
Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes
Soyars, C. L., Peterson, B. A., Burr, C. A., & Nimchuk, Z. L. (2018) · Plant and Cell Physiology · doi:10.1093/pcp/pcy079 · Cited by 50
Metadata
- Authors
- Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Joung, J Keith
- Sander, Jeffry D
- Venue
- Nature Biotechnology
- Published
- 2013-06-23
- Volume
- 31
- Issue
- 9
- Pages
- 822-826
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC3773023
- OpenAlex
- W2077659966
- Cited by
- 3,292
- References
- 20
- Citations by year
- 2026: 140 · 2025: 181 · 2024: 206 · 2023: 208 · 2022: 246 · 2021: 254 · 2020: 280 · 2019: 274 · 2018: 278 · 2017: 269 · 2016: 314 · 2015: 254 · 2014: 291 · 2013: 90
- FWCI
- 141.80
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Human Genome Research Institute (P50HG005550)
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- CRISPR/Cas9, off-target cleavage, RNA-guided nucleases, mismatch tolerance, genome editing, mutagenesis, human cells, off-target sites
- MeSH terms
- Base Sequence, Endonucleases, Genetic Engineering, Humans, Molecular Sequence Data, Mutagenesis, K562 Cells, HEK293 Cells, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
